home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

174.30 +1.18 (+0.68%)

Streaming Delayed Price Updated: 1:57 PM EST, Jan 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

57 58 Next >

Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt ↗

January 17, 2025

Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company.

Via Benzinga

Topics Government

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 14, 2025

Via Benzinga

FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi ↗

January 14, 2025

FDA reviews Eisai and Biogen's BLA for Leqembi SC-AI, targeting Alzheimer's treatment with home-based weekly autoinjector dosing.

Via Benzinga

FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

January 13, 2025

LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option

From Biogen Inc.

Via GlobeNewswire

Peering Into Biogen's Recent Short Interest ↗

January 09, 2025

Via Benzinga

Sage Therapeutics Stock Eyes Best Day In 5 Years On Biogen’s Unsolicited Bid: Retail Piles In ↗

January 13, 2025

The two companies have collaborated since 2020 on the depression drug Zurzuvae, approved in 2023 by the FDA for treating postpartum depression.

Via Stocktwits

Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts ↗

January 13, 2025

Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's success in postpartum depression.

Via Benzinga

Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge ↗

January 13, 2025

Via Benzinga

Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday ↗

January 13, 2025

Via Benzinga

Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday? ↗

January 13, 2025

Sage Therapeutics reviews Biogen's $7.22 per share acquisition proposal amid ongoing restructuring and focus on Zurzuvae for postpartum depression.

Via Benzinga

17 Analysts Assess Biogen: What You Need To Know ↗

January 02, 2025

Via Benzinga

Assessing Biogen: Insights From 19 Financial Analysts ↗

December 09, 2024

Via Benzinga

Enduring Truths for Investors Both New and Seasoned ↗

January 11, 2025

Via The Motley Fool

Grid Expansion; Beaten Blues ↗

January 08, 2025

While the mega-caps seem to get all the attention these days, there's 1,000s of stocks out there worth researching.

Via Talk Markets

Topics Stocks / Equities

Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected ↗

January 07, 2025

Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data and subgroup analyses in 2025.

Via Benzinga

Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet. ↗

January 07, 2025

One analyst says the six-month study was too short and the benefits could appear over time.

Via Investor's Business Daily

These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024 ↗

January 04, 2025

Via The Motley Fool

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic ↗

January 03, 2025

William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases.

Via Benzinga

10 Worst Performing Large-Caps Last 12 Months ↗

December 26, 2024

Here’s this week’s top 10 worst performing Large-Caps in the last twelve months.

Via Talk Markets

Topics Stocks / Equities

Large-Cap Stocks In Trouble - Saturday, Dec. 21 ↗

December 21, 2024

Over the past 12 months, a group of 10 large-cap stocks have underperformed all others. Here’s an updated look at the top 10 worst performing large-caps, along with their one-year price returns.

Via Talk Markets

Topics Stocks / Equities

This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗

December 20, 2024

Via Benzinga

Super Micro Computer Teeters On Edge Of Nasdaq 100: Can xAI, Nvidia Help Stabilize Trajectory? ↗

December 11, 2024

Super Micro faces potential delisting from Nasdaq 100 Index due to underperformance and auditing scandal. Uncertainty surrounds its future.

Via Benzinga

Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown ↗

December 09, 2024

Jefferies downgrades Biogen with a reduced price target, citing pipeline setbacks, slow Leqembi sales, and challenges from declining Ocrevus royalties.

Via Benzinga

This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗

December 09, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 02, 2024

Via Benzinga

These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over ↗

November 26, 2024

Via The Motley Fool

Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside ↗

November 20, 2024

UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024.

Via Benzinga

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

November 19, 2024

From Biogen Inc.

Via GlobeNewswire

Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026 ↗

November 18, 2024

Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show gradual growth amid market challenges.

Via Benzinga

This Biogen Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗

November 18, 2024

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

57 58 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com